Dexamethasone prodrug emulsion

Drug Profile

Dexamethasone prodrug emulsion

Alternative Names: Cortiject; Dexamethasone palmitate intravitreal injection; Nova 63035; NOVA63035; Ophthalmic corticosteroid prodrug - Santen SAS

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novagali Pharma
  • Developer Santen S.A.S.
  • Class Corticosteroids; Eye disorder therapies
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Diabetic macular oedema

Most Recent Events

  • 24 Sep 2015 Phase I/II development is ongoing in the USA
  • 08 May 2013 Novagali Pharma SAS is now called Santen SAS
  • 07 Feb 2012 Phase-I/II clinical trials in Diabetic macular oedema in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top